Click-Chemistry-Mediated Synthesis of Selective Melanocortin Receptor 4 Agonists.

The melanocortin receptor 4 (MC4R) subtype of the melanocortin receptor family is a target for therapeutics to ameliorate metabolic dysfunction. Endogenous MC4R agonists possess a critical pharmacophore (HFRW), and cyclization of peptide agonists often enhances potency. Thus, 17 cyclized peptides were synthesized by solid phase click chemistry to develop novel, potent, selective MC4R agonists. Using cAMP measurements and a transcriptional reporter assay, we observed that several constrained agonists generated by a cycloaddition reaction displayed high selectivity (223- to 467-fold) toward MC4R over MC3R and MC5R receptor subtypes without compromising agonist potency. Significant variation was also observed between the EC50 values for the two assays, with robust levels of reporter expression measured at lower concentrations than those effecting appreciable increases in cAMP levels for the majority of the compounds tested. Collectively, we characterized significant elements that modulate the activity of the core pharmacophore for MC4R and provide a rationale for careful assay selection for agonist screening.

[1]  M. Meldal,et al.  High Capacity Poly(ethylene glycol) Based Amino Polymers for Peptide and Organic Synthesis , 2004 .

[2]  P Kolb,et al.  GPCRdb: the G protein‐coupled receptor database – an introduction , 2016, British journal of pharmacology.

[3]  Manuela Grimaldi,et al.  1,4-Disubstituted-[1,2,3]triazolyl-Containing Analogues of MT-II: Design, Synthesis, Conformational Analysis, and Biological Activity , 2014, Journal of medicinal chemistry.

[4]  C. Haskell-Luevano,et al.  Structure-activity relationships (SAR) of melanocortin and agouti-related (AGRP) peptides. , 2010, Advances in experimental medicine and biology.

[5]  M. Bednarek,et al.  Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Journal of medicinal chemistry.

[6]  K. Freeman,et al.  Synthesis and Pharmacology of α/β(3)-Peptides Based on the Melanocortin Agonist Ac-His-dPhe-Arg-Trp-NH2 Sequence. , 2015, ACS medicinal chemistry letters.

[7]  Paolo Grieco,et al.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. , 2002, Journal of medicinal chemistry.

[8]  K. Clément,et al.  Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. , 2016, The New England journal of medicine.

[9]  J. Macor,et al.  beta-alanine dipeptides as MC4R agonists. , 2003, Bioorganic & medicinal chemistry letters.

[10]  V J Hruby,et al.  alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. , 1987, Journal of medicinal chemistry.

[11]  M. Bednarek,et al.  Analogs of Lactam Derivatives of α-Melanotropin with Basic and Acidic Residues , 2000 .

[12]  A. Edison,et al.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R). , 2013, Journal of medicinal chemistry.

[13]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[14]  Molly E. Martin,et al.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[15]  B. Farmer,et al.  An improved method for the determination of cross-relaxation rates from NOE data , 1986 .

[16]  C. Saper,et al.  Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat , 2003, The Journal of comparative neurology.

[17]  M. Culler,et al.  Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice , 2009, Peptides.

[18]  M. R. Hayes,et al.  Melanocortin control of energy balance: evidence from rodent models , 2011, Cellular and Molecular Life Sciences.

[19]  S. Garland.  Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.

[20]  V. Hruby,et al.  Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors. , 2015, Journal of medicinal chemistry.

[21]  M. Świtoński,et al.  Family of melanocortin receptor (MCR) genes in mammals—mutations, polymorphisms and phenotypic effects , 2013, Journal of Applied Genetics.

[22]  P. Prusis,et al.  Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. , 1997, European journal of pharmacology.

[23]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[24]  Ying-kui Yang.  Structure, function and regulation of the melanocortin receptors. , 2011, European journal of pharmacology.

[25]  Ximena Opitz-Araya,et al.  Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides , 1997, Cell.

[26]  Jinfa Ying,et al.  Solution structures of cyclic melanocortin agonists and antagonists by NMR. , 2003, Biopolymers.

[27]  M. Bednarek,et al.  Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin☆ ☆ Throughout this report, the numbering of the amino acid residues in α-MSH has been retained for all linear and cyclic peptides. , 1999, Peptides.

[28]  E. Lalli,et al.  Signal transduction and gene regulation: the nuclear response to cAMP. , 1994, The Journal of biological chemistry.

[29]  M. Montminy,et al.  Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB , 1988, Nature.

[30]  P. Emmerson,et al.  Discovery of a β-MSH-derived MC-4R selective agonist , 2005 .

[31]  Xin-jie Chu,et al.  Structure–activity relationship of cyclic peptide penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH2 at the human melanocortin-1 and -4 receptors: His6 substitution , 2003 .

[32]  Esther C Y Lee,et al.  Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008-2014). , 2015, Pharmaceutical patent analyst.

[33]  M. Tota,et al.  Molecular determinants of ligand binding to the human melanocortin-4 receptor. , 2000, Biochemistry.

[34]  Xin-jie Chu,et al.  Structure-activity relationship of linear peptide Bu-His6-DPhe7-Arg8-Trp9-Gly10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution. , 2003, Bioorganic & medicinal chemistry letters.

[35]  M. Meldal,et al.  A single-vector EYFP reporter gene assay for G protein-coupled receptors. , 2015, Analytical biochemistry.

[36]  I. Hall,et al.  Agonist Actions of “β-Blockers” Provide Evidence for Two Agonist Activation Sites or Conformations of the Human β1-Adrenoceptor , 2003 .

[37]  C. Pouton,et al.  Synthesis and biological evaluation of alpha-MSH analogues substituted with alanine. , 1994, Peptides.

[38]  Morten Meldal,et al.  Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. , 2002, The Journal of organic chemistry.

[39]  V. Hruby,et al.  [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Prokop,et al.  MOLECULAR EVOLUTION OF GPCRS Melanocortin/melanocortin receptors , 2014 .

[41]  K. Narayan,et al.  Obesity in Low- and Middle-Income Countries: Burden, Drivers, and Emerging Challenges. , 2017, Annual review of public health.

[42]  J. Burbach,et al.  Conformation of the Core Sequence in Melanocortin Peptides Directs Selectivity for the Melanocortin MC3 and MC4 Receptors* , 1999, The Journal of Biological Chemistry.

[43]  P. Grieco,et al.  Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. , 2003, The journal of peptide research : official journal of the American Peptide Society.

[44]  G. Bray,et al.  Potent and Selective Agonism of the Melanocortin Receptor 4 With MK‐0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy , 2009, Clinical pharmacology and therapeutics.

[45]  M. Mulholland,et al.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists. , 2005, Biochemistry.

[46]  T. Gudermann,et al.  Exchange factors directly activated by cAMP mediate melanocortin 4 receptor-induced gene expression , 2016, Scientific Reports.

[47]  V. Hruby,et al.  Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. , 1996, Life sciences.

[48]  R. Ruel,et al.  β-Alanine dipeptides as MC4R agonists , 2003 .

[49]  P. Prusis,et al.  Selectivity of Cyclic [d-Nal7] and [d-Phe7] Substituted MSH Analogues for the Melanocortin Receptor Subtypes , 1997, Peptides.

[50]  J. Wikberg,et al.  Selectivity of [Phe-I7], [Ala6], and [d-Ala4,Gln5,Tyr6] Substituted ACTH(4-10) Analogues for the Melanocortin Receptors , 1997, Peptides.

[51]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[52]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[53]  P. Prusis,et al.  Design of new small cyclic melanocortin receptor-binding peptides using molecular modelling: Role of the His residue in the melanocortin peptide core. , 2001, European journal of medicinal chemistry.

[54]  J. Haycock,et al.  Melanocortin signalling mechanisms. , 2010, Advances in experimental medicine and biology.

[55]  Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Biochemical and biophysical research communications.

[56]  L. Pardo,et al.  Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR. , 2012, Nature chemical biology.

[57]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[58]  C. Pouton,et al.  Synthesis and biological evaluation of α-MSH analogues substituted with alanine , 1994, Peptides.

[59]  David C Fry,et al.  A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides. , 2004, Bioorganic & medicinal chemistry.

[60]  K. Lindsten,et al.  Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells , 2000, Nature Biotechnology.

[61]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[62]  D. Fisher,et al.  Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning , 2006, Nature.

[63]  M. Bednarek,et al.  Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. , 1999, Biochemical and biophysical research communications.

[64]  Tim Cheetham,et al.  Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. , 2003, The New England journal of medicine.

[65]  Xin-jie Chu,et al.  Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides. , 2005, Bioorganic & medicinal chemistry letters.

[66]  Paolo Grieco,et al.  Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. , 2002, Journal of medicinal chemistry.

[67]  A. Levine,et al.  Synthesis, Biophysical, and Pharmacological Evaluation of the Melanocortin Agonist AST3-88: Modifications of Peptide Backbone at Trp 7 Position Lead to a Potent, Selective, and Stable Ligand of the Melanocortin 4 Receptor (MC4R) , 2014, ACS chemical neuroscience.

[68]  C. Haskell-Luevano,et al.  The 1,4-benzodiazepine-2,5-dione small molecule template results in melanocortin receptor agonists with nanomolar potencies. , 2008, Journal of medicinal chemistry.

[69]  Robert Fredriksson,et al.  The GRAFS classification system of G-protein coupled receptors in comparative perspective. , 2005, General and comparative endocrinology.

[70]  Zhimin Xiang,et al.  Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.

[71]  M. Meldal,et al.  Cu‐Catalyzed Azide—Alkyne Cycloaddition , 2008 .

[72]  Y. Iwakura,et al.  Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis , 2007, Proceedings of the National Academy of Sciences.

[73]  David L Smiley,et al.  Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold. , 2005, Bioorganic & medicinal chemistry letters.

[74]  C. Haskell-Luevano,et al.  Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors. , 2016, ACS chemical neuroscience.

[75]  M. Bednarek,et al.  Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin. , 1999, Peptides.

[76]  R. Dores,et al.  60 YEARS OF POMC: Melanocortin receptors: evolution of ligand selectivity for melanocortin peptides. , 2016, Journal of molecular endocrinology.

[77]  R. Cone,et al.  Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions☆ , 2000, Peptides.

[78]  R. Maki,et al.  Functional Selectivity of Melanocortin 4 Receptor Peptide and Nonpeptide Agonists: Evidence for Ligand-Specific Conformational States , 2005, Journal of Pharmacology and Experimental Therapeutics.

[79]  D. Cross-Doersen,et al.  End-capping of the modified melanocortin tetrapeptide (p-Cl)Phe-D-Phe-Arg-Trp-NH2 as a route to hMC4R agonists. , 2004, Bioorganic & medicinal chemistry letters.

[80]  V. Hruby,et al.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Meldal,et al.  Peptidotriazoles: Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions on Solid-Phase , 2001 .

[82]  J. Hoyer,et al.  Modulation of blood pressure by central melanocortinergic pathways. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[83]  David E. Gloriam,et al.  Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.

[84]  Mark D. Ericson,et al.  A Macrocyclic Agouti-Related Protein/[Nle4,DPhe7]α-Melanocyte Stimulating Hormone Chimeric Scaffold Produces Subnanomolar Melanocortin Receptor Ligands. , 2017, Journal of medicinal chemistry.

[85]  Xin-jie Chu,et al.  Structure-activity relationship of cyclic peptide penta-c[Asp-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys]-NH(2) at the human melanocortin-1 and -4 receptors: His(6) substitution. , 2003, Bioorganic & medicinal chemistry letters.

[86]  Michael G Kelly,et al.  Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2). , 2003, Bioorganic & medicinal chemistry letters.

[87]  W. Elliott.  Modulation of Blood Pressure by Central Melanocortinergic Pathways , 2010 .

[88]  D. Tobin,et al.  Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. , 2006, The Journal of investigative dermatology.

[89]  P. Emmerson,et al.  Discovery of a beta-MSH-derived MC-4R selective agonist. , 2005, Journal of Medicinal Chemistry.

[90]  M. Tota,et al.  The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. , 2002, European journal of pharmacology.

[91]  V. Hruby.  Design of cyclic peptides with biological activities from biologically active peptides: the case of peptide modulators of melanocortin receptors , 2016, Biopolymers.

[92]  W. Gispen,et al.  Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. , 1999, European journal of pharmacology.

[93]  I. Hall,et al.  Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. , 2004, Molecular pharmacology.

[94]  C. Butts,et al.  Interproton distance determinations by NOE--surprising accuracy and precision in a rigid organic molecule. , 2011, Organic & biomolecular chemistry.